Approach, Technical Success, Complications, and Stent Patency of Sharp Recanalization for the Treatment of Chronic Venous Occlusive Disease: Experience in 123 Patients

ConclusionSharp recanalization has a high technical success and low rate of adverse events in the recanalization of chronic venous occlusions.
Source: CardioVascular and Interventional Radiology - Category: Radiology Source Type: research

Related Links:

ConclusionsThe overall VTE rate after CABG has been low. However, the condition has been associated with worse 30-day postoperative outcomes and complications. The independent predictors of VTE development included a history of bleeding disorders, congestive heart failure in the 30 days before surgery, and operative time of ≥310 minutes. Understanding these risk factors should aid physicians in the decisions regarding prophylaxis and treatment.
Source: Journal of Vascular Surgery: Venous and Lymphatic Disorders - Category: Surgery Source Type: research
Publication date: Available online 13 October 2019Source: Journal of Vascular Surgery: Venous and Lymphatic DisordersAuthor(s): Katherine L. Morrow, James Bena, Sean P. Lyden, Ezequiel Parodi, Christopher J. SmolockAbstractObjectiveInferior vena cava (IVC) filters have been commonly used to prevent pulmonary embolism in patients with deep vein thrombosis. However, IVC filters have been associated with risks, including IVC perforation, filter migration, fracture, and thrombosis. Filter retrieval has not always been successful. Our objective was to identify the factors associated with failure of retrieval of IVC filters.Meth...
Source: Journal of Vascular Surgery: Venous and Lymphatic Disorders - Category: Surgery Source Type: research
AbstractA false-positive result of syphilis screening test (FPST) is a characteristic finding in patients with systemic lupus erythematosus (SLE). We evaluated the clinical characteristics of SLE patients with FPST at SLE diagnosis. We reviewed the medical records of patients with SLE who underwent the Venereal Disease Research Laboratory or Rapid Plasma Reagin tests at SLE diagnosis at Severance Hospital between 2006 and 2016. The baseline characteristics and clinical outcomes were compared between patients with FPST and those with a negative result of syphilis screening test. Of 145 patients with SLE, 20 patients showed ...
Source: Rheumatology International - Category: Rheumatology Source Type: research
U.S. FDA approves rivaroxaban to help prevent blood clots in acutely ill medical patientsA new oral option for patients in the U.S. with acute medical illnesses at risk for thromboembolic complications who are not at high risk of bleeding / Rivaroxaban is the only non vitamin K antagonist oral anticoagulant (NOAC) approved in the U.S for the continuum of venous thromboembolism (VTE) care, from prevention and treatment of initial VTE through extended prevention of recurrent VTEmehr ...
Source: Bayer IR Newsfeed: Events - Category: Pharmaceuticals Source Type: news
[Premium Times] Air travellers face increased risk of thrombosis and should pay more attention to condition that involves poor blood flow and clotting, a haematologist has said.
Source: AllAfrica News: Health and Medicine - Category: African Health Source Type: news
XARELTO ® provides a new oral option to help prevent venous thromboembolism (VTE) and VTE-related death during hospitalization and post-hospital discharge in acutely ill medical patients at risk for VTE and not at high risk of bleedingDespite being largely preventable, VTE, or blood clots, remains a signif icant risk for millions of Americans hospitalized with an acute medical illness
Source: Johnson and Johnson - Category: Pharmaceuticals Source Type: news
A new oral option for patients in the U.S. with acute medical illnesses at risk for thromboembolic complications who are not at high risk of bleeding / Rivaroxaban is the only non vitamin K antagonist oral anticoagulant (NOAC) approved in the U.S for the continuum of venous thromboembolism (VTE) care, from prevention and treatment of initial VTE through extended prevention of recurrent VTE
Source: Bayer Company News - Category: Pharmaceuticals Source Type: news
Publication date: Available online 12 October 2019Source: The Lancet Respiratory MedicineAuthor(s): Stefano Barco, Seyed Hamidreza Mahmoudpour, Luca Valerio, Frederikus A Klok, Thomas Münzel, Saskia Middeldorp, Walter Ageno, Alexander T Cohen, Beverley J Hunt, Stavros V KonstantinidesSummaryBackgroundEuropean estimates of the burden imposed by pulmonary embolism are not available to this date. We aimed to assess pulmonary embolism-related mortality and time trends in the WHO European Region.MethodsWe analysed vital registration data from the WHO Mortality Database (2000–15) covering subregions of the WHO Europea...
Source: The Lancet Respiratory Medicine - Category: Respiratory Medicine Source Type: research
AbstractPulmonary thromboembolism (PTE) is an acute and severe disease with high mortality, which is prone to be misdiagnosed or ignored especially when complicated with tuberculosis  (TB). Even though TB has been considered as a risk factor for PTE, there is rare report of TB with PTE worldwide. Which TB patients are more susceptible to PTE is still not clear. Here, we described a case report of PTE with pulmonary TB in a 28-year-old man, who had no risk factors for pulmonary thrombosis at admission and developed a medium-high PTE after initiating anti-TB therapy. After local thrombolysis with interventional the...
Source: Journal of Thrombosis and Thrombolysis - Category: Hematology Source Type: research
Authors: Gong M, Zhao B, He X, Gu J, Chen G Abstract The aim of the present study was to investigate whether the rescue of thrombolysis with the recombinant tissue plasminogen activator (rt-PA) alteplase was an effective and safe therapeutic option in patients who did not respond to urokinase. Between February 2016 and February 2017, 26 patients with deep venous thrombosis (DVT) underwent rescue thrombolysis with alteplase. Unsuccessful thrombolysis with urokinase was defined as a lack of improvement in the degree of thrombotic removal with a lysis rate 3 million units of total urokinase, or>7 days infusion dura...
Source: Experimental and Therapeutic Medicine - Category: General Medicine Tags: Exp Ther Med Source Type: research
More News: Angioplasty | Baloon Angioplasty | Cardiology | Cardiovascular | Central Venous Catheterization | Heart | Radiology | Thrombosis | Women